Cat. No.: HY-N0416

Cucurbitacin B

13 Cited Publications

Avis client

Based on 13 publication(s) in Google Scholar

Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.81%
CAS No.: 6199-67-3
Formule: C₃₂H₄₆O₈
Masse moléculaire:558.70

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cucurbitacin B Chemical Structure

CAS No.: 6199-67-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase :

Voir tous les produits spécifiques à Isoform Integrin :

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Voir tous les produits spécifiques à Isoform COX :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.088 μM Compound: CuB; 1	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
BXPC-3	IC₅₀	0.022 μM Compound: CuB; 1	Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
CFPAC-1	IC₅₀	0.023 μM Compound: CuB; 1	Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
CHO	IC₅₀	1.99 μM Compound: 2	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 30108825]
HCT-116	IC₅₀	0.019 μM Compound: CuB; 1	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
HeLa	IC₅₀	0.024 μM Compound: CuB; 1	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
HepG2	IC₅₀	0.051 μM Compound: CuB; 1	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
Huh-7	IC₅₀	4.1 μM Compound: 6; CuB	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38382391]
L02	IC₅₀	0.011 μM Compound: CuB; 1	Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
LNCaP	IC₅₀	0.1 μM Compound: 18	Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability by CellTitre-Glo assay Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability by CellTitre-Glo assay	[PMID: 37428122]
LNCaP	IC₅₀	0.1 μM Compound: 8	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 30195238]
MCF7	IC₅₀	0.04 μM Compound: CuB; 1	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
MCF7	IC₅₀	12 μM Compound: CuB	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]
MCF7	IC₅₀	9.72 μM Compound: CuB	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay	[PMID: 31620225]
MDA-MB-231	IC₅₀	0.037 μM Compound: CuB; 1	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
PANC-1	IC₅₀	0.067 μM Compound: CuB; 1	Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
PC-3	IC₅₀	0.1 μM Compound: 8	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 30195238]
SK-OV-3	IC₅₀	0.047 μM Compound: CuB; 1	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
Vero	IC₅₀	0.04 μM Compound: CuB	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]

In Vitro

Cucurbitacin B (up to 40 μM, 12-48 h) inhibits the cell growth and arrests cell cycle progression at the G2/M phase in CCA cell lines ^[2].
Cucurbitacin B (0.1, 0.3 and 1 μM) increases the level of total superoxide dismutase(T-SOD) and SOD-1, but decrease the reactive oxygen species (ROS) and malondialdehyde (MDA) in BY4741 yeast cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

CCA cell lines
Concentration:

0.1, 1 0.5, 1,5, 10, 20, 40 μM
Incubation Time:

24 and 48 h
Result:

Decreased cell viability in a dose-dependent and time-dependent manner with the IC₅₀ values of 13:44 μM for 24 h and 1.55 for 48 h.

Cell Cycle Analysis^[2]

Cell Line:

CCA cell lines
Concentration:

0.1, 1, 10 μM
Incubation Time:

24 h
Result:

Arrested cell cycle progression at the G2/M phase.

Western Blot Analysis^[2]

Cell Line:

CCA cell lines
Concentration:

0.1, 1 0.5, 1,5, 10, 20, 40 μM
Incubation Time:

12 and 24 h
Result:

Decreased the expression of Cyclin A, Cyclin D1, Cdc25A, but increased the level of p21.

In Vivo

Cucurbitacin B (5 mg/kg, oral administration 10day) B shows protective effects against carrageenan-induced prostatitis in rats^[4].
Cucurbitacin B (20-50 mg/kg for i.p., 28 day) B afford a decline in AD symptoms and protects neurons against STZ-ICV toxicity that improved memory functions in rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Carrageenan-induced prostatic inflammation in rats^[4]
Dosage:

5mg/kg/day for 10day
Administration:

Oral administration
Result:

Decreased the level of TNF-α, IL-1b, COX-2 and iNOS in prostatic tissues.

Animal Model:

STZ-ICV rat prototype of AD-like dementia^[5]
Dosage:

20, 50mg/kg/day for 28days
Administration:

Intraperitoneal injection (i.p.)
Result:

Decreased the TNF-α, IL-1β, MPO, iNOS, acetylcholinesterase, and glutamate levels, but increased gamma-aminobutyric acid.
Increase in viable neuron density in the cortex and hippocampus of rats.

Chemical Information

CAS No. 6199-67-3
Appearance Solid
Masse moléculaire 558.70
Formule C₃₂H₄₆O₈
Color White to off-white
SMILES

O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C([C@@H](O)C[C@@]4([H])[C@]3(C)C2=O)=O
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (13)

All WBCell Proliferation/Viability AssayCell Imaging/StainingFlow CytometryRT-PCR

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May;155:104751. PMID: 32151678
Biomacromolecules

2026 May 11;27(5):3080-3108. PMID: 41950466
Mech Ageing Dev

AMPK alleviates oxidative stress‑induced premature senescence via inhibition of NF-κB/STAT3 axis-mediated positive feedback loop. [Abstract]

2020 Oct;191:111347. PMID: 32882228

Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]

H₂O₂-treated NIH3T3 cells were incubated in complete medium with different STAT3 inhibitors including AG490 (50 μM), Stattic (0.5 μM), Cucurbitacin B (CuB, 40 ng/mL), S3I-201 (50 μM) and NF-κB inhibitor QNZ (5 μM) for 3 days. Cells lysates were subjected to immunoblotting. The results showed that Cucurbitacin B reduced the expression of p21.

Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]

H₂O₂-treated NIH3T3 cells were incubated in complete medium with different STAT3 inhibitors including AG490 (50 μM), Stattic (0.5 μM), Cucurbitacin B (CuB, 40 ng/mL), S3I-201 (50 μM) and NF-κB inhibitor QNZ (5 μM) for 3 days. Cells were stained for SA-β-Gal and quantified.

Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]

H₂O₂-treated NIH3T3 cells were incubated in complete medium with different STAT3 inhibitors including AG490 (50 μM), Stattic (0.5 μM), Cucurbitacin B (CuB, 40 ng/mL), S3I-201 (50 μM) and NF-κB inhibitor QNZ (5 μM) for 3 days. qRT-PCR analyses of SASP factors expression.
Int J Mol Sci

Cucurbitacin B Inhibits the Proliferation of WPMY-1 Cells and HPRF Cells via the p53/MDM2 Axis. [Abstract]

2024 Aug 28;25(17):9333. PMID: 39273281

Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 28;25(17):9333. [Abstract]

Effect of Cucurbitacin B (Cu B) on the cell viability of WPMY-1 and HPRF. Cu B and Doxa inhibited the proliferation of WPMY-1 and HPRF cells based on CCK-8 results. Prostate cells were treated with vehicle (0.1% DMSO), doxazosin (40 μM), or Cu B (12.5 nM, 25 nM, 50 nM, 100 nM, 200 nM) for 48 h and 72 h. The positive control drug doxazosin 40 μM significantly reduced the survival rate of both cells compared with the solvent control group. After 72 h of treatment with Cu B at medium to high concentrations (25 nM–200 nM), the survival rate of WPMY-1 cells was significantly reduced compared with the solvent control group. Only after 72 h of treatment with the highest concentration (200 nM) of Cu B was the survival rate of HPRF cells significantly reduced compared with the solvent control group.

Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 28;25(17):9333. [Abstract]

Apoptosis of WPMY-1 and HPRF that were treated with Cucurbitacin B (Cu B) and Doxa. Cu B and Doxa induced the apoptosis of prostate cells based on the results of flow cytometry analysis. In WPMY-1 cells, the apoptosis rate of the Doxa group and the middle-to-high concentration Cu B (50 nM–100 nM; 48 h) group was significantly increased compared with the control group. In HPRF cells, only the apoptosis rate of the high-concentration Cu B (50 nM–100 nM; 48 h) group was significantly increased compared with the control group.
Int J Mol Sci

The Antiproliferative and Proapoptotic Effects of Cucurbitacin B on BPH-1 Cells via the p53/MDM2 Axis. [Abstract]

2023 Dec 28;25(1):442. PMID: 38203613
Int Immunopharmacol

2026 Jun 13:185:116985. PMID: 42287958
Int Immunopharmacol

Cucurbitacin B suppresses malignant progression of oral leukoplakia via ferroptosis-induced macrophage polarization. [Abstract]

2025 Sep 13:165:115485. PMID: 40946669
AMB Express

Cucurbitacin B alleviates DSS-induced ulcerative colitis by improving gut microbiota disorder in C57BL/6 mice. [Abstract]

2025 Jul 26;15(1):111. PMID: 40715887
Int J Immunopathol Pharmacol

Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice. [Abstract]

2025 Jan-Dec:39:3946320251348715. PMID: 40518910
J Insect Sci

The Modulation of Trehalose Metabolism by 20-Hydroxyecdysone in Antheraea pernyi (Lepidoptera: Saturniidae) During its Diapause Termination and Post-Termination Period. [Abstract]

2020 Sep 1;20(5):18. PMID: 33057682
Electronic Theses and Dissertations

2023 Jul.
Patent

US20220162561A1.
J Nanomater

2021 Mar 12.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (178.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7899 mL

8.9493 mL

17.8987 mL

5 mM

0.3580 mL

1.7899 mL

3.5797 mL

10 mM

0.1790 mL

0.8949 mL

1.7899 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (283 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Dai S, , et al. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics. Pharmacol Res. 2023;187:106587. [Content Brief]

[2]. Klungsaeng, et al. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. Am J Chin Med. 2020;48(6):1475-1489. [Content Brief]

[3]. Lin Y, et al. Cucurbitacin B Exerts Antiaging Effects in Yeast by Regulating Autophagy and Oxidative Stress. Oxid Med Cell Longev. 2019;2019:4517091. [Content Brief]

[4]. Aljohani OS. Phytochemical evaluation of Cucumis prophetarum: protective effects against carrageenan-induced prostatitis in rats. Drug Chem Toxicol. 2022;45(4):1461-1469. [Content Brief]

[5]. Liu Z, Kumar M, Kabra A. Cucurbitacin B exerts neuroprotection in a murine Alzheimer's disease model by modulating oxidative stress, inflammation, and neurotransmitter levels. Front Biosci (Landmark Ed). 2022;27(2):71. [Content Brief]

[6]. Shang Y, et al. Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN. Eur Rev Med Pharmacol Sci. 2014;18(21):3297-303. [Content Brief]

[7]. Zhang M, et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep. 2014 Dec;10(6):2905-11. [Content Brief]

[8]. Guo J, et al. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. PLoS One. 2014 Feb 4;9(2):e88140. [Content Brief]

[9]. Gupta P, et al. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget. 2014 Apr 15;5(7):1812-28. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7899 mL	8.9493 mL	17.8987 mL	44.7467 mL
	5 mM	0.3580 mL	1.7899 mL	3.5797 mL	8.9493 mL
	10 mM	0.1790 mL	0.8949 mL	1.7899 mL	4.4747 mL
	15 mM	0.1193 mL	0.5966 mL	1.1932 mL	2.9831 mL
	20 mM	0.0895 mL	0.4475 mL	0.8949 mL	2.2373 mL
	25 mM	0.0716 mL	0.3580 mL	0.7159 mL	1.7899 mL
	30 mM	0.0597 mL	0.2983 mL	0.5966 mL	1.4916 mL
	40 mM	0.0447 mL	0.2237 mL	0.4475 mL	1.1187 mL
	50 mM	0.0358 mL	0.1790 mL	0.3580 mL	0.8949 mL
	60 mM	0.0298 mL	0.1492 mL	0.2983 mL	0.7458 mL
	80 mM	0.0224 mL	0.1119 mL	0.2237 mL	0.5593 mL
	100 mM	0.0179 mL	0.0895 mL	0.1790 mL	0.4475 mL

Cucurbitacin B

13 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Cucurbitacin B

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Flavor Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cucurbitacin B

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase

Voir tous les produits spécifiques à Isoform Integrin

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Voir tous les produits spécifiques à Isoform COX

Activité biologique

Chemical Information

Publications (13)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Cucurbitacin B Related Classifications

HY-N0416 Related Classifications